Opinion
Video
JAK Inhibitors vs Cytokine Inhibitors: AAD 2025 Findings on Infection Risks
A panelist discusses how the comprehensive ADVANCES safety monitoring system data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) revealed distinct infection risk profiles between Janus kinase (JAK) inhibitors (upadacitinib/abrocitinib, n = 1686) and cytokine inhibitors (dupilumab/tralokinumab, n = 3352) in atopic dermatitis patients, with JAK inhibitors showing elevated relative risks for serious infections and Candida infections during the 180-day assessment period, potentially influencing treatment selection based on individual patient risk factors.
• Please discuss the data presented at AAD 2025 on the cohort study detailing results from the ADVANCES safety monitoring system, regarding serious infections in patients with atopic dermatitis treated with either JAK inhibitors or cytokine inhibitors.
o What was the objective of this study?
o How was this study designed/what methodology was used?
o What results were presented?
n = 1686 on upadacitinib/abrocitinib
n = 3352 on dupilumab/tralokinumab
o 180-day risk of serious infection – RR
o 180-day risk of candida infection – RR
• Please share your key takeaways from this study. How might the results impact your decisions for atopic dermatitis?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
